Evogene和Pure Capital Group达成合作协议

Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries

its goal of becoming a world leader in AI-driven small-molecule discovery and optimization for the pharmaceutical and ag-chemical industries

At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters.

the reconstituted Board will comprise seven directors, including four nominated by the Pure Capital Group

Evogene Ltd. (Nasdaq: EVGN ) (TASE: EVGN)

Under the terms of the Agreement, two current directors, Dr. Yael Margolin and Mr. Yoshinori Oikawa, who resigned from the Board will be replaced by Pure Capital Group nominees Dr.

REHOVOT, Israel , Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN ) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a…